Your browser doesn't support javascript.
loading
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial.
Chen, Jinhua; Jin, Pengfei; Chen, Xiaoqi; Mao, Qunying; Meng, Fanyue; Li, Xinguo; Chen, Wei; Du, Meizhi; Gao, Fan; Liu, Pei; Li, Xiujuan; Guo, Changfu; Xie, Tingbo; Lu, Weiwei; Li, Qingliang; Li, Li; Yan, Xing; Guo, Xiang; Du, Hongqiao; Li, Xiuling; Duan, Kai; Zhu, Fengcai.
Afiliación
  • Chen J; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Jin P; Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Chen X; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Mao Q; Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Meng F; Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Li X; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Chen W; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Du M; Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China.
  • Gao F; Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Liu P; School of Public Health, Southeast University, Nanjing, Jiangsu, China.
  • Li X; Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China.
  • Guo C; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Xie T; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Lu W; Department of Research and Development, National Vaccine & Serum Institute, Beijing, China.
  • Li Q; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Li L; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Yan X; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Guo X; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Du H; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Li X; Department of Research and Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.
  • Duan K; Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.
  • Zhu F; Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.
Hum Vaccin Immunother ; 18(5): 2063630, 2022 11 30.
Article en En | MEDLINE | ID: mdl-35714273
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enterovirus / Enterovirus Humano A Tipo de estudio: Clinical_trials Límite: Child / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enterovirus / Enterovirus Humano A Tipo de estudio: Clinical_trials Límite: Child / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos